期刊文献+

Design and synthesis of 3'-(prop-2-yn-1-yloxy)-biphenyl substituted cyclic acylguanidine compounds as BACE1 inhibitors

Design and synthesis of 3'-(prop-2-yn-1-yloxy)-biphenyl substituted cyclic acylguanidine compounds as BACE1 inhibitors
原文传递
导出
摘要 Based on the lead compounds 1 and 2, a series of novel BACE1 inhibitors were designed and synthesized,among which compound 9h exhibited a 60 fold improvement in potency over the lead compound 1. This represents a good lead for the discovery of more promising BACE1 inhibitors for the potential treatment of AD. The result also showed that the prop-2-yn-1-yloxy is a suitable fragment for modification of cyclic acylguanidine BACE1 inhibitors. Based on the lead compounds 1 and 2, a series of novel BACE1 inhibitors were designed and synthesized,among which compound 9h exhibited a 60 fold improvement in potency over the lead compound 1. This represents a good lead for the discovery of more promising BACE1 inhibitors for the potential treatment of AD. The result also showed that the prop-2-yn-1-yloxy is a suitable fragment for modification of cyclic acylguanidine BACE1 inhibitors.
出处 《Chinese Chemical Letters》 SCIE CAS CSCD 2016年第6期961-963,共3页 中国化学快报(英文版)
基金 supported by grants from The National Natural Science Foundation of China (No. 81172924) Beijing Municipal Natural Science Foundation (No. 7112106)
关键词 Alzheimer’s disease BACE1 inhibitor Prop-2-yn-1-yloxy Cyclic acylguanidine Alzheimer’s disease BACE1 inhibitor Prop-2-yn-1-yloxy Cyclic acylguanidine
  • 相关文献

参考文献1

二级参考文献12

  • 1J.A. Hardy, G.A. Higgins, Alzheimer's disease: the amyloid cascade hypothesis, Science 256 (1992) 184-185.
  • 2D.J. Selkoe, Translating cell biology into therapeutic advances in Alzheimer's disease, Nature 399 (1999) A23-A31.
  • 3Y. Hamada, Y. Kiso, Recent progress in the drug discovery of non-peptidic BACEI inhibitors, Expert Opin. Drug Discov. 4 (2009) 391-416.
  • 4Z.N. Zhu, Z.Y. Sun, Y.Z. Ye, et al., Discovery of cyclic acylguanidines as highly potent and selective [B-site amyloid cleaving enzyme (BACE) inhibitors: Part l-inhibitor design and validation, J. Med. Chem. 53 (2010) 951-965.
  • 5Z.N. Zhu, lminoheterocycle as a druggable motif: BACE1 inhibitors and beyond, Trends Pharmacol. SCi. 33 (2012) 233-240.
  • 6M.S. Wolfe, Secretase targets for Alzheimer's disease: identification and thera- peutic potential, J. Med. Chem. 44 (2001) 2039-2060.
  • 7IL Silvestri, Boom in the development of non-peptidic 13-Secretase (BACE1) inhibitors for the treatment of Alzheimer's disease, Med. Res. Rev. 29 (2009) 295-338.
  • 8. D. Oehlrich, H. Prokopcova, H.J.M. Gijsen, The evolution of amidine-based brain penetrant BACE1 inhibitors, Bioorg. Med. Chem. Lett. 24 (2014) 2033-2045.
  • 9I.D, Scott, A.W. Stamford, E.]. Gilbert, .N. Cumming, Iminothiadiazine dioxide compounds as BACE inhibitors, compositions and their use, WO2011044181AI.
  • 10J.N. Cumming, E.M. Smith, L.Y. Wang, et al., Structure based design of iminohy- dantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor, Bioorg. Med. Chem. Lett. 22 (2012) 2444-2449.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部